Top

Published in:

Open Access 01-12-2023 | Frontotemporal Dementia | Research

Peripheral inflammation in behavioural variant frontotemporal dementia: associations with central degeneration and clinical measures

Authors: Min Chu, Lulu Wen, Deming Jiang, Li Liu, Haitian Nan, Ailing Yue, Yingtao Wang, Yihao Wang, Miao Qu, Ningqun Wang, Liyong Wu

Published in: Journal of Neuroinflammation | Issue 1/2023

Abstract

Background

Neuroinflammation plays a significant role in the progression of frontotemporal dementia (FTD). However, the association between peripheral inflammatory factors and brain neurodegeneration is poorly understood. We aimed to examine changes in peripheral inflammatory markers in patients with behavioural variant FTD (bvFTD) and explore the potential association between peripheral inflammation and brain structure, metabolism, and clinical parameters.

Methods

Thirty-nine bvFTD patients and 40 healthy controls were enrolled and underwent assessment of plasma inflammatory factors, positron emission tomography/magnetic resonance imaging, and neuropsychological assessments. Group differences were tested using Student’s t test, Mann‒Whitney U test, or ANOVA. Partial correlation analysis and multivariable regression analysis were implemented using age and sex as covariates to explore the association between peripheral inflammatory markers, neuroimaging, and clinical measures. The false discovery rate was used to correct for the multiple correlation test.

Results

Plasma levels of six factors, including interleukin (IL)-2, IL-12p70, IL-17A, tumour necrosis superfamily member 13B (TNFSF/BAFF), TNFSF12 (TWEAK), and TNFRSF8 (sCD30), were increased in the bvFTD group. Five factors were significantly associated with central degeneration, including IL-2, IL-12p70, IL-17A, sCD30/TNFRSF8, and tumour necrosis factor (TNF)-α; the association between inflammation and brain atrophy was mainly distributed in frontal–limbic–striatal brain regions, whereas the association with brain metabolism was mainly in the frontal–temporal–limbic–striatal regions. BAFF/TNFSF13B, IL-4, IL-6, IL-17A and TNF-α were found to correlate with clinical measures.

Conclusion

Peripheral inflammation disturbance in patients with bvFTD participates in disease-specific pathophysiological mechanisms, which could be a promising target for diagnosis, treatment, and monitoring therapeutic efficacy.

Available only for authorised users

Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M, Chute DJ, Roberson ED, Pace-Savitsky C, Neumann M, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol. 2005;62:925–30.PubMedCrossRef

Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013;9:176–88.PubMedCrossRef

Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz-Ramirez G, Jiao J, Zhang Z, Huang EJ, Gao FB, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33:5352–61.PubMedPubMedCentralCrossRef

O’Rourke JG, Bogdanik L, Yáñez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324–9.PubMedPubMedCentralCrossRef

Bussian TJ, Aziz A, Meyer CF, Swenson BL, van Deursen JM, Baker DJ. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562:578–82.PubMedPubMedCentralCrossRef

Bossù P, Salani F, Alberici A, Archetti S, Bellelli G, Galimberti D, Scarpini E, Spalletta G, Caltagirone C, Padovani A, Borroni B. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J Neuroinflammation. 2011;8:65.PubMedPubMedCentralCrossRef

Katisko K, Solje E, Korhonen P, Jääskeläinen O, Loppi S, Hartikainen P, Koivisto AM, Kontkanen A, Korhonen VE, Helisalmi S, et al. Peripheral inflammatory markers and clinical correlations in patients with frontotemporal lobar degeneration with and without the C9orf72 repeat expansion. J Neurol. 2020;267:76–86.PubMedCrossRef

Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, Diehl-Schmid J, Andersen PM, Kornhuber J, Danek A, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90:4–10.PubMedCrossRef

Lant SB, Robinson AC, Thompson JC, Rollinson S, Pickering-Brown S, Snowden JS, Davidson YS, Gerhard A, Mann DM. Patterns of microglial cell activation in frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2014;40:686–96.PubMedCrossRef

10.

Bellucci A, Bugiani O, Ghetti B, Spillantini MG. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis. 2011;8:221–9.PubMedPubMedCentralCrossRef

11.

Taipa R, Brochado P, Robinson A, Reis I, Costa P, Mann DM, Melo Pires M, Sousa N. Patterns of microglial cell activation in Alzheimer disease and frontotemporal lobar degeneration. Neurodegener Dis. 2017;17:145–54.PubMedCrossRef

12.

Bright F, Werry E, Dobson-Stone C, Piguet O, Ittner L, Halliday G, Hodges J, Kiernan M, Loy C, Kassiou M, Kril J. Neuroinflammation in frontotemporal dementia. Nat Rev Neurol. 2019;15:540–55.PubMedCrossRef

13.

Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777–83.PubMedCrossRef

14.

Swift IJ, Sogorb-Esteve A, Heller C, Synofzik M, Otto M, Graff C, Galimberti D, Todd E, Heslegrave AJ, van der Ende EL, et al. Fluid biomarkers in frontotemporal dementia: past, present and future. J Neurol Neurosurg Psychiatry. 2021;92:204–15.PubMedCrossRef

15.

Vieira ÉLM, Caramelli P, Rocha NP, Freitas Cardoso MDG, de Miranda AS, Teixeira AL, de Souza LC. Tumor necrosis factor superfamily molecules are increased in behavioral variant frontotemporal dementia and correlate with cortical atrophy: an exploratory investigation. J Neuroimmunol. 2021;354: 577531.PubMedCrossRef

16.

Deverman BE, Patterson PH. Cytokines and CNS development. Neuron. 2009;64:61–78.PubMedCrossRef

17.

Boulanger LM. Immune proteins in brain development and synaptic plasticity. Neuron. 2009;64:93–109.PubMedCrossRef

18.

Rascovsky K, Hodges J, Knopman D, Mendez M, Kramer J, Neuhaus J, van Swieten J, Seelaar H, Dopper E, Onyike C, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.PubMedPubMedCentralCrossRef

19.

Gerrits E, Giannini LAA, Brouwer N, Melhem S, Seilhean D, Le Ber I, Kamermans A, Kooij G, de Vries HE, Boddeke E, et al. Neurovascular dysfunction in GRN-associated frontotemporal dementia identified by single-nucleus RNA sequencing of human cerebral cortex. Nat Neurosci. 2022;25:1034–48.PubMedCrossRef

20.

Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, Siao CJ, Brydges S, LaRosa E, Bai Y, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;6:23204.PubMedPubMedCentralCrossRef

21.

Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, Suzuki-Uematsu S, Ghosh S, Singh A, Merkle FT, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8:347ra393.CrossRef

22.

Galimberti D, Bonsi R, Fenoglio C, Serpente M, Cioffi SM, Fumagalli G, Arighi A, Ghezzi L, Arcaro M, Mercurio M, et al. Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers. Brain Behav Immun. 2015;49:182–7.PubMedCrossRef

23.

Roos P, von Essen MR, Nielsen TT, Johannsen P, Stokholm J, Bie AS, Waldemar G, Simonsen AH, Heslegrave A, Zetterberg H, et al. Inflammatory markers of CHMP2B-mediated frontotemporal dementia. J Neuroimmunol. 2018;324:136–42.PubMedCrossRef

24.

Gibbons L, Rollinson S, Thompson JC, Robinson A, Davidson YS, Richardson A, Neary D, Pickering-Brown SM, Snowden JS, Mann DM. Plasma levels of progranulin and interleukin-6 in frontotemporal lobar degeneration. Neurobiol Aging. 2015;36(1603):e1601-1604.

25.

Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YA, Bresolin N, Scarpini E. Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2006;66:146–7.PubMedCrossRef

26.

Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, Cortini F, Scalabrini D, Baron P, Vergani C, et al. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer’s disease and frontotemporal lobar degeneration. J Neurol. 2008;255:539–44.PubMedCrossRef

27.

Sjögren M, Folkesson S, Blennow K, Tarkowski E. Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry. 2004;75:1107–11.PubMedPubMedCentralCrossRef

28.

Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, Criswell LA, Jaeger PA, Stan T, Heggeli KA, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry. 2013;84:956–62.PubMedCrossRef

29.

Fraga VG, Magalhães CA, Loures CMG, de Souza LC, Guimarães HC, Zauli DAG, Carvalho MDG, Ferreira CN, Caramelli P, de Sousa LP, Gomes KB. Inflammatory and pro-resolving mediators in frontotemporal dementia and Alzheimer’s disease. Neuroscience. 2019;421:123–35.PubMedCrossRef

30.

Rainero I, Rubino E, Cappa G, Rota E, Valfrè W, Ferrero P, Fenoglio P, Baci D, D’Amico G, Vaula G, et al. Pro-inflammatory cytokine genes influence the clinical features of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 2009;27:543–7.PubMedCrossRef

31.

Krabbe G, Minami SS, Etchegaray JI, Taneja P, Djukic B, Davalos D, Le D, Lo I, Zhan L, Reichert MC, et al. Microglial NFκB-TNFα hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia. Proc Natl Acad Sci U S A. 2017;114:5029–34.PubMedPubMedCentralCrossRef

32.

Chu M, Liu L, Wang J, Liu L, Kong Y, Jing D, Xie K, Cui Y, Cui B, Zhang J, et al. Investigating the roles of anterior cingulate in behavioral variant frontotemporal dementia: a PET/MRI study. J Alzheimers Dis. 2021;84:1771–9.PubMedPubMedCentralCrossRef

33.

Liu L, Chu M, Nie B, Liu L, Xie K, Cui Y, Kong Y, Chen Z, Nan H, Chen K, et al. Reconfigured metabolism brain network in asymptomatic microtubule-associated protein tau mutation carriers: a graph theoretical analysis. Alzheimers Res Ther. 2022;14:52.PubMedPubMedCentralCrossRef

34.

Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, Kramer JH, Weiner M, Miller BL, Seeley WW. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer’s disease. Brain. 2010;133:1352–67.PubMedPubMedCentralCrossRef

35.

Zhou J, Seeley WW. Network dysfunction in Alzheimer’s disease and frontotemporal dementia: implications for psychiatry. Biol Psychiatry. 2014;75:565–73.PubMedCrossRef

36.

Pitel AL, Aupée AM, Chételat G, Mézenge F, Beaunieux H, de la Sayette V, Viader F, Baron JC, Eustache F, Desgranges B. Morphological and glucose metabolism abnormalities in alcoholic Korsakoff’s syndrome: group comparisons and individual analyses. PLoS ONE. 2009;4: e7748.PubMedPubMedCentralCrossRef

37.

Segobin S, La Joie R, Ritz L, Beaunieux H, Desgranges B, Chételat G, Pitel AL, Eustache F. FDG-PET contributions to the pathophysiology of memory impairment. Neuropsychol Rev. 2015;25:326–55.PubMedCrossRef

38.

Woollacott IOC, Swift IJ, Sogorb-Esteve A, Heller C, Knowles K, Bouzigues A, Russell LL, Peakman G, Greaves CV, Convery R, et al. CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia. Ann Clin Transl Neurol. 2022;9:1764–77.PubMedPubMedCentralCrossRef

39.

Woollacott IOC, Nicholas JM, Heslegrave A, Heller C, Foiani MS, Dick KM, Russell LL, Paterson RW, Keshavan A, Fox NC, et al. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimers Res Ther. 2018;10:79.PubMedPubMedCentralCrossRef

40.

Sandiego CM, Gallezot JD, Pittman B, Nabulsi N, Lim K, Lin SF, Matuskey D, Lee JY, O’Connor KC, Huang Y, et al. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci U S A. 2015;112:12468–73.PubMedPubMedCentralCrossRef

41.

Luu TG, Kim HK. (18)F-Radiolabeled Translocator Protein (TSPO) PET tracers: recent development of TSPO radioligands and their application to PET study. Pharmaceutics. 2022;14:2545.PubMedPubMedCentralCrossRef

42.

Ching AS, Kuhnast B, Damont A, Roeda D, Tavitian B, Dollé F. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging. 2012;3:111–9.PubMedCrossRef

43.

Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004;56:894–7.PubMedCrossRef

Title: Peripheral inflammation in behavioural variant frontotemporal dementia: associations with central degeneration and clinical measures
Authors: Min Chu
Lulu Wen
Deming Jiang
Li Liu
Haitian Nan
Ailing Yue
Yingtao Wang
Yihao Wang
Miao Qu
Ningqun Wang
Liyong Wu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Frontotemporal Dementia
Frontotemporal Dementia
Dementia
Dementia
Published in: Journal of Neuroinflammation / Issue 1/2023
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-023-02746-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Peripheral inflammation in behavioural variant frontotemporal dementia: associations with central degeneration and clinical measures

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Infiltrating myeloid cell-derived properdin markedly promotes microglia-mediated neuroinflammation after ischemic stroke

TNFR1 signaling converging on FGF14 controls neuronal hyperactivity and sickness behavior in experimental cerebral malaria

The aging ovary impairs acute stroke outcomes

Repeated closed-head mild traumatic brain injury-induced inflammation is associated with nociceptive sensitization

SAFit2 ameliorates paclitaxel-induced neuropathic pain by reducing spinal gliosis and elevating pro-resolving lipid mediators

Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity